Redenlab chosen for new multinational natural history study in Dentatorubral-pallidoluysian atrophy (DRPLA)
Redenlab Inc, the speech neuroscience company delivering insights in communication testing, announces that it has been selected by USA and UK based charities to support their upcoming natural history study in Dentatorubral-pallidoluysian atrophy (DRPLA). Conducted across 4 sites in 2 countries over 3 years, the study will investigate how the disease evolves over time in children and adults with DRPLA. For the study, Redenlab will provide advanced speech recording and analysis solutions as well as quantitative swallowing assessments.
DRPLA is a brain disorder that worsens over time. It can lead to involuntary movements, mental and emotional problems, and a decline in thinking ability. Symptoms usually appear around 30 years of age, but can occur anytime from infancy to mid-adulthood. Specific signs and symptoms may differ and include seizures, issues with balance and coordination (ataxia), and involuntary muscle jerking or twitching (myoclonus). DRPLA is caused by a mutation in the ATN1 gene and is inherited in an autosomal dominant manner. [see rarediseases.info.nih.gov/ for more information]
Adam Vogel PhD, Chief Science Officer of Redenlab, commented:
“Redenlab is delighted to be awarded the contract for this new DRPLA natural history study. With limited longitudinal data and a relatively undefined trajectory of decline for communication, understanding how DRPLA changes over time presents a significant challenge for future trial design. In order to prepare the field for clinical trials to come, this natural history study represents a substantial step towards trial preparedness. We are proud to support the sponsors in their tireless efforts to bring a better understanding to this devastating disease. This recent award reflects the confidence our partners place in Redenlab as the trusted speech neuroscience company for their DRPLA innovations.”